| scholarly article | Q13442814 |
| MDMA | Q69488 |
| P6179 | Dimensions Publication ID | 1017683029 |
| P356 | DOI | 10.1016/S0893-133X(98)00013-X |
| P698 | PubMed publication ID | 9718588 |
| P5875 | ResearchGate publication ID | 13566106 |
| P2093 | author name string | T Huber | |
| F X Vollenweider | |||
| A Gamma | |||
| M Liechti | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| P304 | page(s) | 241-251 | |
| P577 | publication date | 1998-10-01 | |
| P1433 | published in | Neuropsychopharmacology | Q2261280 |
| P1476 | title | Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers | |
| P478 | volume | 19 |
| Q51073688 | (+/-)-3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats. |
| Q47777762 | (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA. |
| Q34565712 | 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings |
| Q34190116 | A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA |
| Q64070251 | A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy |
| Q35851128 | A developmental comparison of the neurobehavioral effects of ecstasy (MDMA) |
| Q35604001 | A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans |
| Q35105559 | Acute Psychological and Neurophysiological Effects of MDMA in Humans |
| Q44885616 | Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat. |
| Q33907331 | Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans |
| Q38962662 | Altered Insula Connectivity under MDMA. |
| Q35095703 | Altered states: the clinical effects of Ecstasy. |
| Q43241590 | Amphetamine analogs methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) differentially affect speech |
| Q44588974 | Angry cognitive bias, trait aggression and impulsivity in substance users |
| Q38160918 | Anxiolytic drug discovery: what are the novel approaches and how can we improve them? |
| Q30473430 | Brain mechanisms of hallucinogens and entactogens |
| Q37192598 | Bruxism physiology and pathology: an overview for clinicians |
| Q51381678 | Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. |
| Q34280452 | Chronic depersonalization following illicit drug use: a controlled analysis of 40 cases. |
| Q24633299 | Club drugs: review of the 'rave' with a note of concern for the Indian scenario |
| Q50682130 | Cognitive disorders after sporadic ecstasy use? A case report. |
| Q46160331 | Comment on the letter by Green, Gabrielsson, Marsden, and Fone, MDMA: on the translation from rodent to human dosing. |
| Q52803481 | Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder. |
| Q40594777 | Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. |
| Q36617655 | Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes |
| Q57176236 | Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine |
| Q44400666 | Differences Between Ecstasy-Using and Nonusing Methamphetamine Users |
| Q35965775 | Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats |
| Q35017128 | Differential effects of cocaine and MDMA self-administration on cortical serotonin transporter availability in monkeys |
| Q47318737 | Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. |
| Q37416406 | Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice |
| Q24658430 | Disposition of MDMA and metabolites in human sweat following controlled MDMA administration |
| Q37082483 | Ecstasy (MDMA) and oral health |
| Q37318873 | Ecstasy produces left ventricular dysfunction and oxidative stress in rats |
| Q44418655 | Ecstasy: a review of scientific literature about MDMA |
| Q35607891 | Effect of 8-hydroxy-2-(N,N-di-n-propylamino)tetralin and MDMA on the discriminative stimulus effects of the classical hallucinogen DOM in rats |
| Q34367545 | Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain |
| Q44823747 | Effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') on the jaw-opening reflex and on the alpha-adrenoceptors which regulate this reflex in the anesthetized rat. |
| Q34391195 | Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats |
| Q44721288 | Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safety |
| Q37226598 | Effects of MDMA on body temperature in humans |
| Q36357993 | Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors |
| Q37402587 | Effects of acute 3,4-methylenedioxymethamphetamine on sleep and daytime sleepiness in MDMA users: a preliminary study. |
| Q43196887 | Effects of repeated MDMA administration on the motivation for palatable food and extinction of operant responding in mice |
| Q38480514 | Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users |
| Q44541736 | Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine |
| Q34634128 | Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users |
| Q35078880 | Gene expression analysis indicates CB1 receptor upregulation in the hippocampus and neurotoxic effects in the frontal cortex 3 weeks after single-dose MDMA administration in Dark Agouti rats |
| Q58803214 | Gene expression analysis indicates reduced memory and cognitive functions in the hippocampus and increase in synaptic reorganization in the frontal cortex 3 weeks after MDMA administration in Dark Agouti rats |
| Q37315499 | Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines |
| Q36316039 | Highs and lows: patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand |
| Q54697388 | Hyperthermia Severely Affects the Vascular Effects of MDMA and Metabolites in the Human Internal Mammary Artery In Vitro. |
| Q28365378 | In vitro neuronal and vascular responses to 5-HT in rats chronically exposed to MDMA |
| Q28218753 | In vitro neuronal and vascular responses to 5-hydroxytryptamine: modulation by 4-methylthioamphetamine, 4-methylthiomethamphetamine and 3,4-methylenedioxymethamphetamine |
| Q42659793 | Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA). |
| Q26859367 | Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans |
| Q36965878 | MDMA 'ecstasy' increases cerebral cortical perfusion determined by bolus-tracking arterial spin labelling (btASL) MRI |
| Q38128525 | MDMA (ecstasy) enhances loud noise-induced morphofunctional alterations in heart and adrenal gland |
| Q37043838 | MDMA Impairs Response to Water Intake in Healthy Volunteers |
| Q34325163 | MDMA alters emotional processing and facilitates positive social interaction |
| Q47901966 | MDMA does not alter responses to the Trier Social Stress Test in humans |
| Q21558551 | MDMA for the treatment of mood disorder: all talk no substance? |
| Q40977003 | MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor. |
| Q40028400 | MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. |
| Q36151338 | MDMA-like behavioral effects of N-substituted piperazines in the mouse |
| Q33961393 | Mental disorders in ecstasy users: a prospective-longitudinal investigation |
| Q73371204 | Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms |
| Q55043421 | Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): Neurodegeneration versus Neuromodulation. |
| Q34976260 | Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. |
| Q44730984 | Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender |
| Q51976287 | N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks. |
| Q36435611 | Natural Selection, Childrearing, and the Ethics of Marriage (and Divorce): Building a Case for the Neuroenhancement of Human Relationships. |
| Q24619949 | Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA) |
| Q48369906 | Neural effects of MDMA as determined by functional magnetic resonance imaging and magnetic resonance spectroscopy in awake marmoset monkeys |
| Q43096892 | Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor |
| Q48474049 | Persistent cerebrovascular effects of MDMA and acute responses to the drug |
| Q37113859 | Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds |
| Q26851461 | Pharmacological treatment of anxiety disorders: current treatments and future directions |
| Q22251113 | Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA) |
| Q36983556 | Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration |
| Q37146495 | Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults |
| Q35105557 | Preventing Problems in Ecstasy Users: Reduce Use to Reduce Harm |
| Q30458761 | Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. |
| Q44894621 | Psychedelic drugs: the ups and downs of ecstasy |
| Q35489276 | Psychostimulants and movement disorders |
| Q28210514 | Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP |
| Q44835541 | Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. |
| Q36803318 | Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users |
| Q47310452 | Social cognition and interaction in chronic users of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). |
| Q34303433 | Substance of abuse and movement disorders: complex interactions and comorbidities |
| Q34524956 | Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study |
| Q47640031 | The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant |
| Q34659485 | The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity |
| Q21558619 | The Potential Dangers of Using MDMA for Psychotherapy |
| Q48149811 | The distribution of 3,4-methylenedioxymethamphetamine "Ecstasy"-induced c-fos expression in rat brain |
| Q34830911 | The effects and consequences of selected club drugs |
| Q50921579 | The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. |
| Q28361466 | The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs |
| Q36734781 | The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review |
| Q35607083 | The role of MDMA (Ecstasy) in coping with negative life situations among urban young adults |
| Q34112933 | The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives |
| Q24606265 | The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study |
| Q43803511 | The subjective effects of MDMA and mCPP in moderate MDMA users |
| Q34142899 | Therapeutic and adverse actions of serotonin transporter substrates |
| Q41254417 | Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy |
| Q46703884 | Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans |
| Q37071511 | Tri-city study of Ecstasy use problems: a latent class analysis. |
| Q35175998 | Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans |
| Q44235411 | Vascular actions of 3,4-methylenedioxymethamphetamine in alpha(2A/D)-adrenoceptor knockout mice |
| Q28365866 | Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat |
| Q52298376 | [Anesthesia in drug addiction]. |
| Q51889564 | [Options, limits and ethics of pharmacological neuroenhancement]. |
| Q44638832 | ‘Ecstasy’-induced subarachnoid haemorrhage: an under-reported neurological complication? |
Search more.